MENS
Jyong Biotech·NASDAQ
--
--(--)
--
--(--)
7.45 / 10
Outperform
Capital flow assessment gives a 7.45/10, indicating robust inflows with a good sentiment score. However, all trend metrics (overall, block, small, medium, large, extra-large) are negative, hinting at short-term pullbacks despite positive momentum. This divergence underscores the importance of timing entries and considering stop-loss strategies to manage volatility.
Fund Flow Rating
What is the analyst consensus for MENS?
- MENS holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.45/10 (Outperform).
